Outsourcing

Annual survey shows strong growth for service providers and promises to continue into 2013.

Jim Miller, president of PharmSource, examines the future direction of CROs/CMOs and the factors influencing the pharmaceutical contract services sectors.

The past three decades have driven a purchasing evolution to a procurement revolution.

A Q&A with Thomas E. D'Ambra, Chairman, CEO, & President of AMRI, on recent industry trends.

Taking time to appreciate the industry's greatest achievements will inspire growth ahead.

Companies roll out expansions in manufacturing high-potency APIs and finished products.

Sponsor companies' increasing focus on strategic outsourcing has changed the rules of the game.

Presidents of leading associations offer views on the industry's future.

Industry wants more innovation, but can suppliers meet customer needs?

Highlights included the latest in pharmaceutical packaging equipment, containers, and labels and new capabilities among contract service providers.

Clinical research organizations see reform in clinical-trial process, including the establishment of chief innovation officer at FDA.

Recovery audits and other past practices in procurement can improve the bottom line.

Apple's experience with manufacturing facilities in China present opportunity for future best practice.

Service providers must focus on delivering a superior customer experience.

Poland's government aims to make the Eastern European country a biotech powerhouse.

Readers share their views on bioprocessing challenges, equipment use, and outsourcing trends in our annual bioprocessing equipment and processing survey.

Collaboration can begin with a conversation.

Recovery audits and other past practices in procurement can improve the bottom line.

Contract API manufacturers and fine-chemical producers roll out capacity and service expansions.

A Q&A with Erik van den Berg, CEO of AM-Pharma, on recent industry trends.

China's drug-distribution network has been a mess for years, but government reforms and industry focus are unveiling new opportunities for market order and growth.

Brazil's generic-drug market is growing steadily.

The evolving bio/pharmaceutical business model poses risk for CMOs.

More collaboration and expanded oversight aim to compel manufacturers to follow GMPs.

Pharma announces plans for the year ahead at annual JPMorgan Global Healthcare conference.